HAEM5:Myeloid proliferations associated with Down syndrome: Difference between revisions
| [unchecked revision] | [checked revision] |
Bailey.Glen (talk | contribs) No edit summary |
Bailey.Glen (talk | contribs) No edit summary |
||
| Line 9: | Line 9: | ||
Note: author needs to merge content from Transient Abnormal Myelopoiesis (TAM) Associated with Down Syndrome AND Myeloid Leukemia Associated with Down Syndrome | Note: author needs to merge content from Transient Abnormal Myelopoiesis (TAM) Associated with Down Syndrome AND Myeloid Leukemia Associated with Down Syndrome | ||
}}</blockquote> | }}</blockquote> | ||
<span style="color:#0070C0">(General Instructions – The main focus of these pages is the clinically significant genetic alterations in each disease type. Use [https://www.genenames.org/ <u>HUGO-approved gene names and symbols</u>] (italicized when appropriate), [https://varnomen.hgvs.org/ HGVS-based nomenclature for variants], as well as generic names of drugs and testing platforms or assays if applicable. Please complete tables whenever possible and do not delete them (add N/A if not applicable in the table and delete the examples). Please do not delete or alter the section headings. The use of bullet points alongside short blocks of text rather than only large paragraphs is encouraged. Additional instructions below in italicized blue text should not be included in the final page content. Please also see </span><u>[[Author_Instructions]]</u><span style="color:#0070C0"> and [[Frequently Asked Questions (FAQs)|<u>FAQs</u>]] as well as contact your [[Leadership|<u>Associate Editor</u>]] or [mailto:CCGA@cancergenomics.org <u>Technical Support</u>])</span> | |||
==Primary Author(s)*== | ==Primary Author(s)*== | ||